Type(s) of breast cancer-Breast carcinoma Posts on Medivizor
Navigation Menu

Type(s) of breast cancer-Breast carcinoma Posts on Medivizor

Endocrine therapy and targeted therapy are safe for patients over 65 with HR+/HER2- advanced breast cancer

Posted by on Dec 30, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to evaluate the effectiveness and safety of endocrine therapy, with or without targeted therapy, for patients with advanced metastatic breast cancer. This study concluded that the use of endocrine therapy and targeted therapy is safe for use in patients over 65.  Some background There are several treatment...

Read More

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer

Posted by on Dec 23, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to determine the effectiveness and safety of ribociclib (Kisqali) combined with a non-steroidal aromatase inhibitor in elderly patients with hormone receptor positive and HER-2 negative breast cancer. This study concluded that ribociclib improved progression free survival and was relatively safe to use...

Read More

Looking at sexual health of breast cancer survivors

Posted by on Sep 30, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the sexual health of breast cancer survivors to that of women from the general population. This study concluded that breast cancer survivors had poorer sexual health when compared to women from the general population.  Some background Post-treatment care is becoming more important in cancer patients...

Read More

ASCO 2017: Breast Cancer Research News

Posted by on Sep 28, 2017 in Breast cancer | 0 comments

Video information: Breast cancer experts gathered at the 2017 American Society of Clinical Oncology meeting to discuss developments in research and treatment. Patient Power founder, Andrew Schorr, was on-site in Chicago and interviewed Dr. Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. Dr. Gralow shares...

Read More

Comparing neoadjuvant options for HER2+ breast cancer

Posted by on Sep 10, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the pathological complete response (pCR) rates of two neoadjuvant therapy combinations for HER2 positive (HER2+, dependent on HER2 for growth) breast cancer. This study concluded that the combination of pertuzumab (Perjeta), trastuzumab (Herceptin) and chemotherapy resulted in higher pCR rates than...

Read More